Zinc acetate
Sources réglementaires consultées
Indications approuvées
- Traitement de la maladie de Wilson.
Contre-indications
Absolues
- Hypersensibilité à la substance active ou à l'un des excipients.
Mises en garde cliniques
- Mise en garde majeure · Il n'est pas recommandé comme traitement initial des patients symptomatiques en raison de son action lente ; ils doivent d'abord recevoir un chélateur et, une fois stabilisés, Wilzin peut être envisagé en entretien. — AEMPS CIMA, Wilzin, ficha técnica 04286001, sección 4.4
- Mise en garde majeure · Surveiller le cuivre plasmatique libre et l'excrétion urinaire du cuivre ; rechercher des signes de carence en cuivre, tels qu'une anémie sidéroblastique ou une leucopénie. — AEMPS CIMA, Wilzin, ficha técnica 04286001, secciones 4.4 y 4.8
Interactions médicamenteuses
- ModéréePénicillamine et trientine
Mécanisme: Les chélateurs peuvent complexer le zinc et réduire l'effet des deux traitements.
Recommandation: Lors du passage à un entretien par Wilzin, coadministrer le chélateur pendant deux à trois semaines et espacer les deux prises d'au moins une heure.
https://cima.aemps.es/cima/dochtml/ft/04286001/FT_04286001.html
Effets indésirables
Communs (≥1%)
Irritation gastrique · Augmentation de l'amylase · Augmentation de la lipase · Augmentation des phosphatases alcalines
Rares mais graves
Anémie sidéroblastique · Leucopénie
Grossesse et allaitement
Pendant la grossesse, le médecin doit décider entre le zinc et un chélateur ; ajuster la dose aux taux de cuivre et surveiller étroitement. Éviter l'allaitement pendant le traitement.
Bibliographie récente (PubMed)
Several features of drug-induced mucosal alterations have been observed in the upper gastrointestinal tract, i.e., the esophagus, stomach, and duodenum. These include pill-induced esophagitis, desquamative esophagitis, worsening of gastroesophageal reflux, chemotherapy-induced esophagitis, proton pump inhibitor-induced gastric mucosal changes, medication-induced gastric erosions and ulcers, pseudomelanosis of the stomach, olmesartan-related gastric mucosal inflammation, lanthanum deposition in the stomach, zinc acetate hydrate tablet-induced gastric ulcer, immune-related adverse event gastritis, olmesartan-asso-ciated sprue-like enteropathy, pseudomelanosis of the duodenum, and lanthanum deposition in the duodenum. For endoscopists, acquiring accurate knowledge regarding these diverse drug-induced mucosal alterations is crucial not only for the correct diagnosis of these lesions but also for differential diag-nosis of other conditions. This minireview aims to provide essential information on drug-induced mucosal alterations observed on esophagogastroduodenoscopy, along with representative endoscopic images.
Zinc is a trace element with a key role in immune function and has demonstrated antiviral and anti-inflammatory properties. Low plasma zinc levels have been associated with poor outcomes in COVID-19. This study aims to evaluate the efficacy and safety of zinc supplementation as an adjuvant therapy in hospitalized patients with COVID-19. A single-center, randomized, open-label clinical trial between May and December 2021. Adults hospitalized with confirmed COVID-19 requiring hospitalization were randomized 1:1 to receive standard of care (SoC) with or without oral zinc acetate (90 mg/day) for 14 days. The primary endpoint was disease progression, defined as critical care requirement (ICU admission) or death. Secondary outcomes included time to clinical recovery, hospital length of stay, WHO clinical scale improvement, inflammatory markers, antibody response, and safety. Seventy-one patients were randomized (35 zinc versus 34 SoC). Disease progression occurred in 5.7 % of the zinc group versus 23.5 % in the SoC group (OR 0.21, 95 %CI = 0.03-0.96,). Mean recovery time was significantly shorter in the zinc group (7.4 ± 6.1 versus 13.1 ± 9.7 days, p = 0.006) and a trend to a faster recovery was observed in the Cox proportional hazards model in the intervention group HR of 1.670 (95 % CI: 0.948-2.942), p = 0.076. WHO scale improvement attaining a < 1 points at day 14 was greater in the zinc group (74.3 % versus 42.4 %, p = 0.009). Antibody levels were higher in the SoC group at days 14 and 28. No adverse events were attributed to zinc. Adjunctive zinc supplementation to standard of care reduced disease progression and showed a trend to accelerated clinical recovery in hospitalized COVID-19 patients, supporting the potential role of zinc in managing viral respiratory infections. ClinicalTrials.gov identifier, NCT05778383.
Zinc is an essential trace element for the maintenance of life because it acts as a center of activity or cofactor for hundreds of enzymes. Zinc deficiency causes a variety of symptoms, including anemia, dermatitis, stomatitis, alopecia, bedsores, decreased appetite, impaired growth, gonadal dysfunction, susceptibility to infection, and taste disorders, etc. In March 2017, zinc acetate hydrate, which had been approved for Wilson disease in Japan, received an additional indication for hypozincemia. Hypozincemia is frequently observed in patients with chronic liver disease (CLD), especially cirrhosis, and it has recently been shown that hypozincemia is closely related to the development of liver fibrosis and increased risk of liver carcinogenesis, in addition to the appearance of various subjective symptoms. Moreover, hypozincemia in CLD may be associated with sarcopenia (i.e., decrease in muscle strength and muscle mass) and frailty (i.e., vulnerability), which receive much attention these days. It is assumed that treatment with zinc acetate hydrate will become widespread in patients with CLD. Zinc acetate hydrate may also have potential for improving sarcopenia in patients with CLD. This review primarily outlines the significance of zinc in patients with CLD.